ClinicalTrials.gg
CompletedNCT05835752Updated Mar 5, 2026

The Safety, Tolerability and Pharmacokinetic Study of RAY1225

A Phase 1 interventional study of RAY1225 and Placebo in Obese and Healthy, sponsored by Guangdong Raynovent Biotech Co., Ltd. Completed at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-05.

Sponsored by Guangdong Raynovent Biotech Co., Ltd (part of Guangdong Zhongsheng Pharmaceutical Co., Ltd.) · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
68
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 600 studies in Obesity with a site in China — 221 open to participants now, 282 under way, 67 of them phase 3. Obesity · China.

Enrollment
343rd of 502
68 · median 120
Started
2023
with 49 others
Phase 1
93 of 600
29 open now
Registered
210th of 600
by date

Among the 600 studies in Obesity with a site in China, this one is the 343rd largest by enrollment of the 502 interventional ones that give a count, is one of 50 that started in 2023, is one of 93 in phase 1, and was the 210th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.

Browse Obesity studies →

Open to participants now

221 of the 600 studies in Obesity with a site in China are open now. Recruiting first, the newest first:

216 more — sign in →

All 221 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 1,339 Obesity studies recruiting now, 377 (28%) set no upper age limit and 859 (64%) stop at 75 or younger; 167 take children under 18; 490 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 600 studies in Obesity with a site in China, or all of them as a file.
02

Study summary

This trial is conducted in China. The aim of the trial is to investigate safety, tolerability, pharmacokinetics and pharmacodynamics of RAY1225

03

Conditions studied

  • Obese
  • Healthy

Browse trials for

Keywords

  • obesity
  • GLP-1
  • GIP
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signature of a dated Form (ICF) indicating that the subject has been informed of all the relevant aspects(including adverse events) of the trial prior to enrollment.
  2. Participants must be willing and able to adhere to the visit schedule and protocol requirements and be available to complete the study.
  3. Participants (including partners) must use reliable methods of during the study and until 6 months following the last dose of product.
  4. Body weight is no less than 50 kg in males and no less than 45 kg in females. (BMI) 18≤BMI\<28 kg/m2(Part A\&B only);BMI is determined by the following equation: BMI = weight/height2 (kg/m2).
  5. BMI≥28 kg/m2(Part C only).BMI is determined by the following equation: BMI = weight/height2 (kg/m2).

Exclusion criteria

Exclusion Criteria:

  1. Participants with disorders (including but not limited to, cardiovascular, hepatic, renal, respiratory, gastrointestinal, endocrine, immune, neurological, psychiatric, cutaneous, hematological disorders, retinopathy, and neoplasms etc. )within 24 weeks prior to randomization.
  2. Participants who are not suitable for subcutaneous injections (trauma, surgery, allergies or skin lesions, etc.).
  3. Known history of definite mental illness, such as depression, suicidal ideation, schizophrenia, bipolar disorder.
  4. Have a family or personal history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia (MEN) Syndrome type 2 or with thyroid nodules of unknown etiology found at screening and considered clinically significant by the investigator.
  5. Participants who experienced a grade 3 hypoglycemic event within the 12 months prior to randomization, or experienced a hypoglycemic event (venous or terminal blood glucose \<3 mmol/L ) ≥3 times or with hypoglycemia-related symptoms within 3 months prior to randomization.
  6. Participants with clinically significant abnormalities on , or >450ms, or with a family history of long QT syndrome or a family history of Brugada syndrome.
  7. Participants who planning to use glucagon-like peptide-1 (GLP-1) receptor agonists and GLP1-related drugs or other enteroglucagon peptides(including but not limited to: exenatide, liraglutide, lisnatide, benalutide, dulaglutide, lorcetide, semaglutide, tirzepatide), during the 12 weeks prior to randomization or during the trial.
  8. Participants who undergone major surgery, donated blood/bleeding profusely (> 400 mL) 12 weeks prior to randomization, donated blood/bleeding profusely (>200 mL) 4 weeks prior to randomization,or have a serious infection.
  9. The average daily smoking are more than 5 cigarettes within 12 weeks prior to screening or unwilling to quit smoking during the study period.
  10. Participants who may not complete the study for other reasons or should not be included in the study in the opinion of the investigator.
  11. Known presence of a single genetic mutation, other diseases or medications causing obesity, including but not limited to hypothalamic obesity, pituitary obesity, hypothyroid obesity, Cushing's syndrome, insulinoma, growth hormone deficiency, acromegaly, pseudohypoparathyroidism, hypogonadism, or weight gain caused by increased non-fat content (e.g., edema)[Part C only]
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
68 participants (actual)

Study arms

  • Experimental
    RAY1225(Part A)

    Escalating doses of RAY1225 administered subcutaneously (SC) once in healthy participants.

    Drug: RAY1225

  • Experimental
    Placebo (Part A)

    Placebo administered SC once in healthy participants.

    Drug: Placebo

  • Experimental
    RAY1225 (Part B)

    Escalating doses RAY1225 administered SC once weekly for four weeks in healthy participants.

    Drug: RAY1225

  • Experimental
    Placebo (Part B)

    Placebo administered SC once weekly for four weeks in healthy participants.

    Drug: Placebo

  • Experimental
    RAY1225(Part C)

    Three dose levels of RAY1225 administered SC once weekly for four weeks in participants with Obese.

    Drug: RAY1225

  • Experimental
    Placebo (Part C)

    Placebo administered SC once weekly for four weeks in participants with Obese.

    Drug: Placebo

Interventions

  • Administered SC

  • DrugPlacebo

    Administered SC

  • Administered SC

  • DrugPlacebo

    Administered SC

  • Administered SC

  • DrugPlacebo

    Administered SC

06

What researchers measure

Primary outcomes

  1. Number and severity of participants with Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events(SAE)

    A summary of TEAEs, SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported

    Time frame: Baseline through Day 29 (Part A)

  2. Number and severity of participants with Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events(SAE)

    A summary of TEAEs, SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported

    Time frame: Baseline through Day 64 (QW,Part B&C);baseline through Day 71 (Q2W,Part B&C)

Secondary outcomes

  1. To determine the single oral dose pharmacokinetic profiles of RAY1225(AUC0-∞)

    Time frame: Baseline through Day 29 (Part A)

  2. To determine the multiple oral dose pharmacokinetic profiles of RAY1225(AUC0-∞)

    Time frame: Baseline through Day 64 (QW,Part B&C);baseline through Day 71 (Q2W,Part B&C)

  3. To determine the Pharmacodynamics of RAY1225(Change in Body Weight)

    Time frame: Baseline through Day 64 (QW,Part B&C);baseline through Day 71 (Q2W,Part B&C)

  4. To determine the Pharmacodynamics of RAY1225(Change in Waist circumference)

    Time frame: Baseline through Day 64 (QW,Part B&C);baseline through Day 71 (Q2W,Part B&C)

07

Study locations

1 site
  • Nanfang Hospital,South Medical Hospital
    Guangzhou, Guangdong, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2023 to primary completion in Mar 2024, 9 months.

Of 334 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 9 months is close to that.

Counting every sponsor, half of 439 studies reached it within 11 months; a quarter within 6 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 11, 2023
First posted
Apr 28, 2023
StartActual
May 18, 2023
Primary completionActual
Mar 1, 2024
CompletionActual
Mar 23, 2024
Last update
Mar 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05835752
Responsible party
Sponsor
First posted
Apr 28, 2023
Start date
May 18, 2023
Primary completion
Mar 1, 2024
Completion
Mar 23, 2024
Last update
Mar 5, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bilpatide

Start the discussion